These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 728374)

  • 1. Quantitative abnormality of an Aalpha chain molecular weight form in the fibrinogen of cirrhotic patients.
    Weinstein MJ; Deykin D
    Br J Haematol; 1978 Dec; 40(4):617-30. PubMed ID: 728374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human fibrinogen heterogeneities: determination of the major Aalpha chain derivatives in blood.
    Galanakis DK; Mosesson MW
    Thromb Res; 1983 Aug; 31(3):403-13. PubMed ID: 20217997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.
    Regañón E; Vila V; Aznar J; Garrido G; Estellés A; Berenguer J
    Thromb Res; 1987 Jun; 46(5):705-14. PubMed ID: 3629544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the structural abnormality of fibrinogen Paris I.
    Mosesson MW; Amrani DL; Ménaché D
    J Clin Invest; 1976 Mar; 57(3):782-90. PubMed ID: 1249208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen-fibrin conversion. The mechanism of fibrin-polymer formation in solution.
    Smith GF
    Biochem J; 1980 Jan; 185(1):1-11. PubMed ID: 7378042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of rat fibrinogen and its constituent chains.
    Van Ruijven-Vermeer IA; Nieuwenhuizen W
    Biochem J; 1978 Mar; 169(3):653-8. PubMed ID: 417720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A frameshift mutation in the human fibrinogen Aalpha-chain gene (Aalpha(499)Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo.
    Margaglione M; Vecchione G; Santacroce R; D'Angelo F; Casetta B; Papa ML; Grandone E; Di Minno G
    Thromb Haemost; 2001 Dec; 86(6):1483-8. PubMed ID: 11776317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dimeric Aalpha chain composition of dysfibrinogenemic molecules with mutations at Aalpha 16.
    Meh DA; Siebenlist KR; Galanakis DK; Bergtrom G; Mosesson MW
    Thromb Res; 1995 Jun; 78(6):531-9. PubMed ID: 15714754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of an abnormal fibrinogen by two-dimensional electrophoresis.
    Polack B; Valiron O; Concord E; Freyssinet JM; Hudry-Clergeon G
    Clin Chem; 1984 Dec; 30(12 Pt 1):2093-7. PubMed ID: 6499181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmic degradation of fibrinogen Paris I.
    Budzynski AZ; Marder VJ
    J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residue gamma153Cys is essential for the formation of the complexes Aalphagamma and Bbetagamma, assembly intermediates for the AalphaBbetagamma complex and intact fibrinogen.
    Terasawa F; Fujita K; Okumura N
    Clin Chim Acta; 2005 Mar; 353(1-2):157-64. PubMed ID: 15698603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the physicochemical properties of fragment D derivatives of fibrinogen and fragment D-D of cross-linked fibrin.
    Marder VJ; Budzynski AZ; Barlow GH
    Biochim Biophys Acta; 1976 Mar; 427(1):1-14. PubMed ID: 130927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
    Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
    Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of an antiserum to the carboxymethylated Aalpha chain of human fibrinogen.
    Conkie JA; Davidson JF
    Thromb Haemost; 1978 Jun; 39(3):564-73. PubMed ID: 100895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that heterodimers exist in the fibrinogen Matsumoto II (gamma308N-->K) proband and participate in fibrin fiber formation.
    Okumura N; Terasawa F; Fujita K; Fujihara N; Tozuka M; Koh CS
    Thromb Res; 2002 Aug; 107(3-4):157-62. PubMed ID: 12431483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the terminal degradation products of canine fibrinogen by plasmin.
    Chen JP; Hutchison HT; Nanninga LB; Guest MM
    Biochim Biophys Acta; 1975 Mar; 386(1):69-79. PubMed ID: 123781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome".
    Mosesson MW; Siebenlist KR; Hainfeld Jf; Wall JS; Soria J; Soria C; Caen JP
    J Clin Invest; 1996 May; 97(10):2342-50. PubMed ID: 8636415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights.
    Francis CW; Kraus DH; Marder VJ
    Biochim Biophys Acta; 1983 Apr; 744(2):155-64. PubMed ID: 6404305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble fibrin complexes: separation as a function of pH and characterization.
    Benabid Y; Concord E; Suscillon M
    Thromb Haemost; 1977 Feb; 37(1):144-53. PubMed ID: 14416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.